SCHEMBL267783

SCHEMBL267783

N[C@H](Cc1ccccc1F)[C@@H](O)Cc1ncccc1C(=O)Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.47
KMT2A Q03164 9/20 0.46
MEN1 O00255 8/20 0.46
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
SGMS2 Q8NHU3 1/20 0.46
RAB9A P51151 3/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 2/20 0.43
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
GLA P06280 1/20 0.41
BCAT2 O15382 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
MAPK1 P28482 2/20 0.40
LRRK2 Q5S007 1/20 0.40
KDR P35968 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL268197 0.99 PRKCI (0.46) PRKCIKMT2AMEN1MAPTALDH1A1
SCHEMBL268989 0.87 LMNA (0.45) KMT2AMEN1MAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL270684 0.86 LMNA (0.44) KMT2AMEN1ALDH1A1GAASGMS2
SCHEMBL3987433 0.86 LMNA (0.47) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL268363 0.86 LMNA (0.47) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL268272 0.85 LMNA (0.48) KMT2AMEN1MAPTALDH1A1SGMS2
SCHEMBL269582 0.85 LMNA (0.43) KMT2AMEN1SGMS2RAB9AHTT
Hydrochloric Acid SCHEMBL270565 0.84 LMNA (0.47) KMT2AMEN1MAPTALDH1A1SGMS2
SCHEMBL270014 0.84 ANO1 (0.42) KMT2AMEN1MAPTSGMS2RAB9A
SCHEMBL268667 0.84 MAPK8 (0.47) KMT2AMEN1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 EP disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 EP disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
EP-1912946-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS Eli Lilly and Company (US) 2008-04-23 EP disclosed
WO-2007015767-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed
WO-2007015767-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors DPP4, DPP3, DPP7 PRKCI 3141/4885KMT2A 3516/4885MEN1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.